National Cancer Institute®
Last Modified: October 1, 2002
UI - 12369553
AU - Mistrangelo M; Mobiglia A; Mussa B; Bello M; Pelosi E; Goss M; Bosso MC;
TI - Moro F; Sandrucci S The sentinel node in anal carcinoma.
SO - Tumori 2002 May-Jun;88(3):S51-2
AD - Sugical Oncology Department, University of Turin, Italy. firstname.lastname@example.org
AIMS AND BACKGROUND: Anal cancer is a rare condition. The inguinal lymph nodes are the most common site of metastasis in this neoplasm. The inguinal lymph node status is an important prognostic indicator and the presence of metastases is an independent prognostic factor for local failure and overall mortality. Depending on the primary tumor size and histological differentiation, metastasis to superficial inguinal lymph nodes occurs in 15-25% of cases. METHODS AND STUDY DESIGN: To evaluate the inguinal lymph node status we performed a search for the sentinel node in a female patient affected by squamous and carcinoma. RESULTS: Identification and examination of the sentinel node was positive and postoperative histology showed the presence of bilateral lymph node metastases. CONCLUSIONS: We suggest that examination of the sentinel node in anal cancer could be an efficient way to establish the inguinal lymph node status, which would help the clinician to plan and perform adequate treatment.
UI - 12006515
AU - Klencke B; Matijevic M; Urban RG; Lathey JL; Hedley ML; Berry M;
TI - Thatcher J; Weinberg V; Wilson J; Darragh T; Jay N; Da Costa M; Palefsky JM Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.
SO - Clin Cancer Res 2002 May;8(5):1028-37
AD - Department of Medicine, Division of Medical Oncology, University of California at San Francisco, 94115, USA. email@example.com
High-grade dysplasia induced by high-risk types of human papillomavirus (HPV) precedes invasive cancer in anal squamous epithelium just as it does in the cervix. A therapeutic HPV vaccine strategy as a potential treatment for anal dysplasia was tested in a standard Phase I dose escalation trial. The primary objective was to evaluate the safety of the agent; additional study aims were to evaluate the histological response, immune response, and effect on anal HPV-16 infection. Each subject was treated with four i.m. injections of 50-400 microg of ZYC101 at 3-week intervals. ZYC101 is composed of plasmid DNA encapsulated in biodegradable polymer microparticles. The plasmid DNA encodes for multiple HLA-A2-restricted epitopes derived from the HPV-16 E7 protein, one of two HPV oncoproteins consistently expressed in neoplastic cells. Fifty-six potential anal dysplasia subjects were screened to identify 12 eligible subjects with HPV-16 anal infection and a HLA-A2 haplotype. The investigational agent was well tolerated in all subjects at all dose levels tested. Three subjects experienced partial histological responses, including one of three subjects receiving the 200-microg dose and two subjects at the 400-microg dose level. Using a direct Elispot, 10 of 12 subjects demonstrated increased immune response to the peptide epitopes encoded within ZYC101; each continued to show elevated immune responses 6 months after the initiation of therapy. These results support the continued investigation of a therapeutic vaccination strategy for anal dysplasia.
UI - 11896421
AU - Damin DC; Rosito MA; Gus P; Tarta C; Weindorfer M; Burger MB; Cartell A
TI - Perianal basal cell carcinoma.
SO - J Cutan Med Surg 2002 Jan-Feb;6(1):26-8
AD - Departament of Coloproctologic Surgery, Hospital de Clinicas de Porto Alegre (HCPA), Federal University of Rio Grande do Sul, Porto Alegre, Brazil. firstname.lastname@example.org
BACKGROUND: A case of basal cell carcinoma (BCC) of the perianal region is reported. This tumor is extremely rare in this location and behaves rather innocently. OBJECTIVE: Clinical and histopathologic characteristics of perianal BCC, as well as the choices of treatment, are outlined. CONCLUSION: The tumor should be histologically distinguished from basaloid carcinoma of the anus, which is much more aggressive and metastasizes early, thus requiring a different therapy.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.